Results 161 to 170 of about 4,867,269 (191)
Some of the next articles are maybe not open access.
Treatment of immunoglobulin light chain amyloidosis
Current Hematologic Malignancy Reports, 2009No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients.
Morie A, Gertz, Steven R, Zeldenrust
openaire +2 more sources
Free Light Chains of Immunoglobulins in Amyloidosis
Acta Medica Scandinavica, 1979ABSTRACT Monomeric (M) and dimeric (D) forms of free light chains in serum have been measured by a sensitive radioimmunoassay in eight patients with amyloidosis without monoclonal proteins. Significantly elevated concentrations of D lambda chains were demonstrated in two of four patients with localized amyloidosis.
J, Sølling, K, Sølling
openaire +2 more sources
Systemic Immunoglobulin Light-Chain Amyloidosis
Clinical Lymphoma and Myeloma, 2006Amyloidosis is a rare disease in which amyloid fibrils compromise organ function and lead to death. Systemic immunoglobulin light-chain amyloidosis, usually caused by free light chains (FLCs) made by clonal plasma cells, is the most frequent type. Hereditary and senile systemic amyloidosis are less frequent types.
openaire +2 more sources
Immunoglobulin Light Chain and Systemic Light-Chain Amyloidosis
2007Light-chain amyloidosis (AL) is characterized by the clonal expansion of plasma B cells that secrete large amounts of monoclonal immunoglobulin light chains. The free light chains circulate in serum and form amyloid fibrils on vital organs such as the kidney, heart, and liver causing organ failure and eventually death.
Marina Ramirez-Alvarado +5 more
openaire +1 more source
Stem cell transplantation for immunoglobulin light chain amyloidosis
Current Problems in Cancer, 2017Systemic chemotherapy aimed at eradicating transformed plasma cells is the mainstay of treatment for immunoglobulin light chain amyloidosis (AL). Autologous stem cell transplantation (SCT) is a highly effective treatment for AL and can lead to long term survival in excess of 10 years in patients who achieve complete remission.
Taimur, Sher, Morie A, Gertz
openaire +2 more sources
Diagnosis and Therapy of Immunoglobulin Light Chain Amyloidosis (AL Amyloidosis)
2012Amyloidosis is a group of disorders that have in common the deposition of protein fibrils composed of protofibrils that have a crystallographic β(beta)-pleated sheet structure. Disease results from these proteinaceous deposits in one or more organ systems [1].
Morie A. Gertz, Robert A. Kyle
openaire +1 more source
Flow cytometry in immunoglobulin light chain amyloidosis: Short review
Leukemia Research, 2015Flow cytometry (FCM) has found its application in clinical diagnosis and evaluation of monoclonal gammopathies (MG). Although, research has been mainly focused on multiple myeloma (MM), nowadays FCM becomes to be potential tool in the field of AL amyloidosis.
Jana, Filipova +6 more
openaire +2 more sources
[Treatment strategy for immunoglobulin light chain amyloidosis].
[Rinsho ketsueki] The Japanese journal of clinical hematology, 2021Systemic AL amyloidosis is a disease wherein amyloid proteins derived from monoclonal immunoglobulin light chains produced by abnormal plasma cells are deposited in the tissues through the whole body and cause organ failure. The treatment aims to minimize treatment-related toxicity and mortality to achieve a deeper and more persistent hematologic ...
openaire +1 more source
IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS
2008Morie A. Gertz, Suzanne R. Hayman
openaire +1 more source